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¤ ¤
Purpose: To report a retrospective study into the effects of trials on clinical decision-
making regarding abdominal aortic aneurysm (AAA) patients suitable for both conven-
tional open (OR) and endovascular aneurysm repair (EVAR).
Methods: A questionnaire was sent to 1400 Dutch surgeons and trainees. Interviewees had
to choose between OR and EVAR for AAA patients with and without comorbidity.
Specifically, their preferences before and after the publication of 2 randomized trials
(EVAR-1 and DREAM) were polled.
Results: Of the 524 (37%) questionnaires returned, 223 (43%) respondents treated AAA
patients. Before publication of the trials, 160 (72%) preferred OR for the patient without
comorbidity and 169 (76%) preferred EVAR for the patient with comorbidity. In total, 72
(32%) respondents changed their preference after the trials were published; however, there
was no overall major shift. Focusing on the different cases revealed that the OR preference
was significantly enhanced for the patient without comorbidity (p,0.01), while the EVAR
preference was significantly enhanced for the patient with comorbidity (p,0.05).
Conclusion: The randomized trials have not induced major overall changes in surgical
decision-making for AAA patients suitable for both EVAR and OR.
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Rupture rates rise as abdominal aortic aneur-
ysms (AAA) expand, so the threshold for
surgical intervention is usually 55 mm in
diameter.1 Currently, there are 2 methods to
treat AAA: conventional open repair (OR) or
endovascular aneurysm repair (EVAR). Pro-
spective European and British registries have
shown lower perioperative mortality after
EVAR compared to OR.2,3 However, there is
an increased risk of complications and re-
interventions, mainly caused by incomplete
exclusion of the AAA and structural failure of
the stent-graft.4
The DREAM (Dutch Randomized Endovas-
cular Aneurysm Management) trial was initi-
ated in 1999 to compare the results of OR and
EVAR.5 In this study, 351 AAA patients
anatomically suitable for both procedures
were randomized to either OR (178 patients)
or EVAR (173 patients). At the same time,
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a British randomized trial was initiated with
inclusion criteria similar to the DREAM trial;
the EVAR-1 study enrolled 1082 patients.6
The short-term results of the DREAM and
EVAR-1 trials were almost identical.7,8
DREAM reported a postoperative mortality
risk in EVAR patients of 1.2% against 4.6% in
OR patients. The midterm results were also
similar.9,10 The initial survival advantage of
EVAR disappeared after the first postopera-
tive year. Two years after treatment, the
survival rates were equal at ,90%.
The impact of the DREAM and EVAR-1 trials
on the policy of AAA treatment depends on
their assessment within the surgical commu-
nity. To gain insight into how the results of
the trials have affected the opinion of best
surgical option for an AAA, we devised
a questionnaire to survey all surgeons in
The Netherlands.
METHODS
In The Netherlands, both general and vascu-
lar surgeons conduct vascular surgery. There
are,1000 surgeons and 400 surgical trainees.
About 350 surgeons are certified members of
the Dutch Society for Vascular Surgery. In
November 2005, a blinded questionnaire was
sent to all surgeons and surgical trainees in
The Netherlands. In the questionnaire, the
role and fields of interest of the respondents
were addressed first. Surgeons who were not
taking care of AAA patients were asked to
return the survey without addressing the case
questions. The following dilemma was pre-
sented to respondents who did treat patients
with AAA: You observe 2 patients in your
clinic with an AAA of 65 mm, both anatomi-
cally and clinically perfectly suitable for both
conventional and endovascular treatment:
Patient A: 65 years, no comorbidity
Patient B: 77 years, mild comorbidity
Which treatment for either patient did you
prefer before the publication of the DREAM
and EVAR-1 trials (even if this was a slight and
non-scientific preference), and which do you
prefer after these trial results appeared?
Differences between groups were com-
pared using the Fisher exact test; p,0.05
was considered statistically significant.
RESULTS
Of the ,1400 questionnaires sent, 524 (37%)
were returned. Of these, 223 (43%) indicated
that they treated AAA patients (Table 1). The
answers, stratified by position (Table 2),
show no major differences in outcome
among the different groups. Before publica-
tion of the DREAM and EVAR-1 trials, 160
(72%) respondents would have preferred OR
and 63 (28%) respondents would have pre-
ferred EVAR for the patient without comor-
bidity. After publication of the results, 164
(74%) respondents preferred OR and 59 (26%)
EVAR. For the patient with comorbidity, 54
(24%) respondents preferred OR and 169
(76%) preferred EVAR before the trials were
published. After publication, 58 (26%) pre-
ferred OR and 165 (74%) preferred EVAR.
In all, 72 (32%) respondents changed their
opinion on AAA treatment of patient A or
patient B after the publication of the DREAM
and EVAR-1 trials (Fig. 1). The pre-trial pref-
erence of OR for patient A (72%) was
enhanced (Fig. 2), as significantly more vas-
cular surgeons changed their opinion from
EVAR to OR (17/46, 37%) than from OR to
EVAR (11/103, 11%; p,0.01). The pre-trial
preference of EVAR for patient B (76%) was
¤ ¤
TABLE 1
Responses to the Questionnaire Sent to Dutch Surgeons and Trainees
Residents (n5400) General Surgeons (n5650) Vascular Surgeons (n5350) Total (n51400)
Respondents 131 (33%) 244 (38%) 149 (43%) 524 (37%)
Treat AAA patients 48 (37%) 26 (11%) 149 (100%) 223 (43%)
Vascular surgery is their
primary practice
4 (3%) 0 (0%) 149 (100%) 153 (29%)
¤ ¤
AAA: abdominal aortic aneurysm.
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enhanced significantly by residents and vas-
cular surgeons (p,0.05).
DISCUSSION
The differences in interpretation of the ran-
domized trials comparing conventional and
endovascular AAA repair among the trialists
and the vascular surgery community have
been remarkable. On one hand, better periop-
erative results after EVAR compared to OR
combined with a similar midterm mortality
risk can be used to claim superiority of EVAR
over OR. On the other hand, one may argue
that EVAR has no midterm advantages, is
more expensive, has a higher reintervention
rate, and is therefore inferior to OR. Clearly,
the trials have not established an absolute
preference for EVAR or OR, which is empha-
sized by the results of our questionnaire.
Figure 1¤Percentages of respondents who chan-
ged their opinion on clinical policy of AAA
treatment after the publication of the randomized
trials for patient A (without comorbidity) and/or
patient B (with comorbidity).
Figure 2¤Percentages of respondents who chan-
ged their opinion on clinical policy of AAA
treatment after the publication of the randomized
trials for (A) patient A (without comorbidity) and
(B) patient B (with comorbidity). The respondents
who preferred OR before the trials and EVAR after
the trials are represented by the gray bars; the
respondents who preferred EVAR before the trials
and OR after the trials are represented by the
white bars.
¤ ¤
TABLE 2
Results of the Questionnaire to Dutch Surgeons and Trainees Who Treat AAA Patients
Residents (n548) Surgeons (n526) Vascular Surgeons (n5149) Total (n5223)
OR EVAR OR EVAR OR EVAR OR EVAR
Patient A*
Before trials{ 39 (81%) 9 (19%) 18 (69%) 8 (31%) 103 (69%) 46 (31%) 160 (72%) 63 (28%)
After trials 37 (77%) 11 (23%) 18 (69%) 8 (31%) 109 (73%) 40 (27%) 164 (74%) 59 (26%)
Patient B
Before trials 11 (23%) 37 (77%) 8 (31%) 18 (69%) 35 (24%) 114 (76%) 54 (24%) 169 (76%)
After trials 12 (25%) 36 (75%) 8 (31%) 18 (69%) 38 (25%) 111 (75%) 58 (26%) 165 (74%)
¤ ¤
OR: open repair, EVAR: endovascular aneurysm repair.
* Patient A: 65 years old and no comorbidity; Patient B: 77 years old with mild comorbidity.
{ EVAR-1 and DREAM.
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Although about one third of the respondents
changed their opinion after publication of the
randomized trials, this did not lead to a signif-
icant overall change of AAA treatment policy.
Before and after the trials appeared in print,
,75% of the respondents preferred OR for the
patient without comorbidity and EVAR for the
patient with comorbidity.
However, when focusing on the individual
cases, we noticed interesting shifts. Before
the trials, the major proportion of surgeons
preferred OR for the patient without comor-
bidity (patient A). Among the minority of
surgeons who favored EVAR for this patient,
31% changed their opinion after the trials in
favor of OR, while only 9% of the OR
supporters switched to EVAR. This is quite
surprising as the trials do not provide evi-
dence that OR may be more beneficial for this
patient group. Actually, a recent subgroup
analysis of the DREAM trial suggested
that the opposite might be true; younger
(#70 years) EVAR-treated patients had lower
2-year mortality rates that younger OR-trea-
ted patients.11 Likewise, the EVAR-1 trialists
have suggested that the fitter the patient, the
more the benefit that can be gained from
EVAR over OR. A plausible explanation for the
outcome of the questionnaire is that it is
believed that younger, more fit patients who
are likely to survive the invasive OR pro-
cedure, live longer and thereby have a higher
chance of undergoing reinterventions that
would make EVAR less beneficial. Clearly,
the randomized trials have not provided
evidence for this assumption.
For patient B, the elderly patient with
comorbidity, the pre-trial preference was
76% for EVAR. Of the surgeons who voted
against EVAR, 37% changed their opinion
after the trials in favor of EVAR, while only
14% of the EVAR supporters switched their
preference to OR, which suggests that the
trials have reduced even further the concern
for EVAR treatment in this patient group
despite the absence of trial evidence to
support this notion. This may be due to the
fact that the trials did show that there are no
major short-term EVAR-related complica-
tions, and that most prior EVAR opponents
feared these complications in the older pa-
tient group.
Limitations
Due to the retrospective nature of the study,
it can be argued that it might have been hard
for the respondents to remember their pre-
trials opinion. However, we feel that the
methods used have assessed the perceived
individual change of opinion, which is a nota-
ble measure in itself. Whether this individual
perceived change of mind is an accurate
representation of the actual change of point
of view from pre- to post-trials will remain
unknown.
Another limitation to our study design is the
low response rate (37%), although this is not
uncommon for surveys such as this one. We
carefully assume that the surgeons who are
willing to read and return the survey are the
surgeons who recognize the importance of
clinical trials and the need for exploring their
impact. Almost half of the vascular surgeons
responded, and we expect that these surgeons
have experience in endovascular surgery.
Therefore, the outcome of the survey may
not be completely generalizable to the global
vascular community, but it will likely reflect the
opinion of leading vascular surgeons.
Conclusion
Based on this questionnaire, we believe
that the randomized trials have not induced
major overall changes in surgical decision-
making for AAA patients suitable for both
EVAR and OR.
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